血液系统恶性肿瘤合并急性呼吸窘迫综合征:一项为期一年的全国回顾性队列研究
该研究基于法国国家医院数据库(PMSI),纳入2017年法国ICU收治的18岁以上ARDS患者共12846例,其中HM 990例、实体癌2744例、无癌症组其余患者。主要终点90天死亡率在HM组为64.4%,高于无癌症组的46.6%(p=0.01),与实体癌组的61.4%无显著差异(p=0.09)。HM组气管插管率87.7%,低于实体癌组的90.4%(p=0.02)和无癌症组的91.3%(p<0.01)。HM患者死亡的独立预测因素包括淋巴瘤或急性白血病诊断、年龄、高改良SAPS II评分、肾脏替代治疗、侵袭性真菌感染和脓毒性休克;细菌性肺炎、肺外感染和无创通气为保护因素。
要点
- HM合并ARDS患者90天死亡率为64.4%,显著高于无癌症患者的46.6%(p=0.01),与实体癌患者的61.4%无显著差异(p=0.09)。
- HM组气管插管率为87.7%,低于实体癌组的90.4%(p=0.02)和无癌症组的91.3%(p<0.01)。
- HM患者死亡的独立预测因素包括淋巴瘤或急性白血病诊断、年龄、高改良SAPS II评分、肾脏替代治疗、侵袭性真菌感染和脓毒性休克。
- 细菌性肺炎、肺外感染和无创通气为HM合并ARDS患者死亡的保护因素。
- HM中最常见的恶性肿瘤为非霍奇金淋巴瘤(28.5%)、急性髓系白血病(20.4%)和多发性骨髓瘤(19.7%)。
适用人群与场景
- 2017年法国ICU收治的18岁及以上、诊断为ARDS的患者;按是否合并血液系统恶性肿瘤(HM)、实体癌或无癌症分为三组进行比较。
研究设计与关键结果
- 研究类型:全国回顾性队列研究,数据来自法国国家医院数据库(PMSI);共纳入12846例ARDS患者,其中HM 990例,实体癌2744例。
- 主要终点:HM患者90天死亡率为64.4%,高于无癌症患者的46.6%(p=0.01),与实体癌患者的61.4%无显著差异(p=0.09)。
- 次要终点:HM组气管插管率87.7%,低于实体癌组的90.4%(p=0.02)和无癌症组的91.3%(p<0.01)。
- HM患者死亡的独立预测因素:淋巴瘤或急性白血病诊断、年龄、高改良SAPS II评分、肾脏替代治疗、侵袭性真菌感染、脓毒性休克;细菌性肺炎、肺外感染和无创通气为保护因素。
- HM主要恶性肿瘤类型:非霍奇金淋巴瘤28.5%、急性髓系白血病20.4%、多发性骨髓瘤19.7%。
证据类型、等级与局限
- 证据类型:回顾性队列研究(全国性数据库分析)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 原文未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Acute respiratory distress syndrome (ARDS) occurring in patients with hematological malignancies (HM) is a life-threatening condition with specific features. Mortality rate remains high but improvement has been described over the past several years. We aimed to describe characteristics and outcomes of ARDS in HM patients admitted in French ICUs (Intensive Care Units) during a one year-period. Data for this nationwide cohort study were collected from the French national hospital database (Programme de Médicalisation des Systèmes d'Information (PMSI)). All patients (18 years or older) admitted to French ICUs in 2017 and with a diagnosis of ARDS were included. Three groups were compared according to the presence of an HM, a solid cancer or no cancer. The primary endpoint was 90-day mortality. Secondary endpoints were the description of ICU management, etiologies of ARDS and mortality risk factors.
RESULTS: A total of 12 846 patients with ARDS were included. Among them, 990 had HM and 2744 had a solid cancer. The main malignancies were non-Hodgkin lymphoma (NHL) (28.5%), acute myeloid leukemia (AML) (20.4%) and multiple myeloma (19.7%). Day-90 mortality in patients with HM was higher than in patients with no cancer (64.4% vs. 46.6% p = 0.01) but was not different from that of patients with solid cancer (64.4% vs. 61.4%,p = 0.09). Intubation rate was lower in patients with HM in comparison with both groups (87.7% vs. 90.4% p = 0.02 for patients with solid cancer and 87.7% vs. 91.3%; p < 0.01 with no cancer). Independent predictors of mortality for patients with HM were a diagnosis of lymphoma or acute leukemia, age, a high modified SAPS II score, a renal replacement therapy, invasive fungal infection, and a septic shock. Bacterial pneumonia, extrapulmonary infections and non-invasive ventilation were protective.
CONCLUSION: Mortality remains high in patients with HM admitted in ICU with ARDS in comparison with patients without cancer. Mortality predictors for this population were a diagnosis of lymphoma or acute leukemia, age, a high modified SAPS II score, a renal replacement therapy, invasive fungal infection and a septic shock.
参考来源
- Bris PN, Pauly V, Orleans V, et al. Acute respiratory distress syndrome in patients with hematological malignancies: a one-year retrospective nationwide cohort study. Ann Intensive Care. 2024. PMID: 39259345. doi:10.1186/s13613-024-01373-4
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。